Merck Partners On Alzheimer’s Diagnostic With GE Healthcare
This article was originally published in The Gray Sheet
Merck will use GE Healthcare’s investigational positron emission tomography agent flutemetamol to select patients to enroll in clinical trials for its Alzheimer’s disease drug candidate.
You may also be interested in...
The assay will be used to support patient selection as part of Merck’s ongoing clinical trial program for the MK-8931 Alzheimer’s disease drug candidate.
Imaging stakeholders call for Medicare coverage of beta amyloid positron emission tomography scans to help diagnose and manage dementia patients, but clinical societies warn against using the technology as a screening tool for Alzheimer’s disease. CMS took comments through Nov. 8 on its ongoing national coverage analysis.
The latest product approvals and launches in cardiology, ophthalmology and more.